The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Ulf G. Eriksson

AstraZeneca R&D Mölndal



Name/email consistency: high



  • AstraZeneca R&D Mölndal, Sweden. 2003 - 2006
  • Experimental Medicine, AstraZeneca R&D, Mölndal, Sweden. 2003


  1. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. Eriksson, U.G., Dorani, H., Karlsson, J., Fritsch, H., Hoffmann, K.J., Olsson, L., Sarich, T.C., Wall, U., Schützer, K.M. Drug Metab. Dispos. (2006) [Pubmed]
  2. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Eriksson, U.G., Bredberg, U., Hoffmann, K.J., Thuresson, A., Gabrielsson, M., Ericsson, H., Ahnoff, M., Gislén, K., Fager, G., Gustafsson, D. Drug Metab. Dispos. (2003) [Pubmed]
  3. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eriksson, U.G., Bredberg, U., Gislén, K., Johansson, L.C., Frison, L., Ahnoff, M., Gustafsson, D. Eur. J. Clin. Pharmacol. (2003) [Pubmed]
  4. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Eriksson, U.G., Mandema, J.W., Karlsson, M.O., Frison, L., Gisleskog, P.O., Wählby, U., Hamrén, B., Gustafsson, D., Eriksson, B.I. Clin. Pharmacokinet (2003) [Pubmed]
  5. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Eriksson, U.G., Johansson, S., Attman, P.O., Mulec, H., Frison, L., Fager, G., Samuelsson, O. Clin. Pharmacokinet (2003) [Pubmed]
WikiGenes - Universities